JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB258950

Human LYPLA2 (APT-2) knockout HEK-293T cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

LYPLA2 KO cell lysate available now. KO validated. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 7 bp deletion in exon2.
1 Images
Sanger Sequencing - Human LYPLA2 (APT-2) knockout HEK-293T cell lysate (AB258950)
  • Sanger seq

Unknown

Sanger Sequencing - Human LYPLA2 (APT-2) knockout HEK-293T cell lysate (AB258950)

Homozygous : 7 bp deletion in exon2

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 7 bp deletion in exon2.

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab258950-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human LYPLA2 knockout HEK293T cell lysate", "number":"AB258950-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HEK293T cell lysate", "number":"AB258950-CMP02", "productcode":"" } ] } } }

Properties and storage information

Gene name
LYPLA2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

APT-2 also known as lysophospholipase A2 (lypla2) is an enzyme involved in lipid metabolism. APT-2 has a molecular mass of approximately 25 kDa and is expressed in various tissues including the brain heart and muscle. As an important member of the lipid acyl hydrolase family it removes fatty acids from lysophospholipids. Researchers often use the names anti-APT and anti-ApT in antibody studies targeting this enzyme. APT-2 identification in these tissues highlights its importance in lipid processing and suggests its broader functional implications.
Biological function summary

APT-2 plays a critical role in maintaining phospholipid homeostasis contributing to membrane fluidity and signal transduction. It is involved in hydrolyzing lysophospholipids into lysoglycerophospholipids and free fatty acids. Not part of a complex APT-2 acts as an individual enzyme handling specific substrates in this context. Its activity regulates levels of lipid signaling molecules influencing cellular responses to environmental cues. APT-2 also contributes to energy storage via metabolism of lipid substrates linking its enzymatic activity to broader metabolic pathways.

Pathways

APT-2 holds significance in both metabolic and signaling pathways specifically the glycerophospholipid metabolism and lysophospholipid signaling pathways. It catalyzes reactions key to these pathways and intersects with proteins like phospholipase A2 and PLA2G6. Glycerophospholipid metabolism sees APT-2 breaking down molecules to sustain membrane integrity and cellular communication processes. In lysophospholipid signaling its activity regulates bioactive lipid levels which impact a variety of cellular signaling events showing a well-integrated role in cellular physiology.

The dysfunction of APT-2 links to neurodegenerative diseases and cardiovascular disorders. Altered APT-2 activity is associated with Alzheimer's disease due to disrupted lipid homeostasis and membrane composition. The enzyme's interaction with proteins like phospholipase A2 highlights its involvement in these neurodegenerative processes. Furthermore cardiovascular health implications arise from its role in lysophospholipid metabolism and associated inflammatory responses. Aberrations in APT-2 function can modulate pathways that exacerbate atherosclerosis further connecting its activity to disease states.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com